We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

269 hedge funds and large institutions have $6.9B invested in Iovance Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 86 increasing their positions, 97 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $120M | Put options by funds: $77.8M

51% more capital invested

Capital invested by funds: $4.58B → $6.9B (+$2.32B)

46% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 39

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

7% more funds holding

Funds holding: 252 → 269 (+17)

5.83% more ownership

Funds ownership: 95.58% → 101.41% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 97

Holders
269
Holders Change
+17
Holders Change %
+6.75%
% of All Funds
4.76%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
57
Increased
86
Reduced
97
Closed
39
Calls
$120M
Puts
$77.8M
Net Calls
+$42M
Net Calls Change
+$15.8M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$294M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
3
CCM
Consonance Capital Management
New York
+$67.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$53.1M
5
NAMA
Nikko Asset Management Americas
New York
+$35.9M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$117M
2
ACA
Avoro Capital Advisors
New York
-$80.8M
3
PA
Perceptive Advisors
New York
-$36.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Stifel Financial
126
Stifel Financial
Missouri
$1.5M +$37.4K +941 +3%
ASRS
127
Arizona State Retirement System
Arizona
$1.48M -$24.1K -607 -2%
Federated Hermes
128
Federated Hermes
Pennsylvania
$1.44M +$580K +14,597 +89%
AB
129
Amalgamated Bank
New York
$1.29M -$238 -6 -0%
CSS
130
Cubist Systematic Strategies
Connecticut
$1.28M -$52.3K -1,317 -5%
CRC
131
Curi RMB Capital
Illinois
$1.27M – – –
CS
132
Credit Suisse
Switzerland
$1.21M -$1.18M -29,612 -53%
CIC
133
Carnegie Investment Counsel
Ohio
$1.21M +$1.03M +26,050 New
Handelsbanken Fonder
134
Handelsbanken Fonder
Sweden
$1.16M +$175K +4,400 +21%
ProShare Advisors
135
ProShare Advisors
Maryland
$1.05M -$38.2K -962 -4%
WP
136
Woodline Partners
California
$1M -$7.03M -177,110 -89%
RJA
137
Raymond James & Associates
Florida
$988K -$1.04M -26,151 -55%
US Bancorp
138
US Bancorp
Minnesota
$964K +$319K +8,025 +63%
Verition Fund Management
139
Verition Fund Management
Connecticut
$962K -$592K -14,914 -42%
P8IP
140
Pier 88 Investment Partners
California
$951K -$794K -19,990 -49%
HS
141
HighVista Strategies
Massachusetts
$948K +$143K +3,599 +21%
AAA
142
Affinity Asset Advisors
New York
$909K +$778K +19,600 New
WMSA
143
Weiss Multi-Strategy Advisers
New York
$887K -$851K -21,426 -53%
OC
144
Oppenheimer & Co
New York
$885K -$186K -4,690 -20%
AG
145
Aperio Group
California
$876K +$52.2K +1,316 +7%
FAM
146
Fred Alger Management
New York
$873K -$496K -12,485 -40%
Rafferty Asset Management
147
Rafferty Asset Management
New York
$866K -$1.74M -43,929 -70%
Janus Henderson Group
148
Janus Henderson Group
United Kingdom
$834K +$715K +18,004 New
State of Wisconsin Investment Board
149
State of Wisconsin Investment Board
Wisconsin
$822K -$29.8K -750 -4%
SMH
150
Sanders Morris Harris
Texas
$820K – – –
4 5
6
7 8

IOVA Hedge Fund Activity: Q4 2020 in Review

269 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2020, worth a combined $6.9B — up 51% from $4.58B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new IOVA positions and 39 closed out — a net gain of 18 holders — while 86 added to existing stakes and 97 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $294M. The largest seller was Great Point Partners, cutting an estimated $117M.

  • 269 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2020, up from 252 in Q3 2020.
  • Funds reported $6.9B of Iovance Biotherapeutics stock for Q4 2020, up 51% quarter-over-quarter.
  • 57 funds opened new Iovance Biotherapeutics positions in Q4 2020 and 39 closed out, a net change of +18 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $294M added.
  • The largest Iovance Biotherapeutics seller in Q4 2020 was Great Point Partners, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.